Biotechnology

miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies

miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.

BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.

Biointron introduces RushData platform for AI-driven antibody discovery

Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.

Cellares and Papillon partner for PPL-001 manufacturing automation

Cellares and Papillon Therapeutics have entered a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for Friedreich’s ataxia (FA), a rare inherited neurodegenerative disorder.

EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.

Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND) application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.